The implications of pharmacogenomics in the treatment of HIV-1-infected patients of African descent

Pharmacogenomics and Personalized Medicine

Volumn 2, Issue 1, 2009, Pages 93-99

  Clarke, Hector ^a   Mousa, Shaker A ^a  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

African populations; AIDS; Genetics; HIV; Personalized medicine; Pharmacotherapy; Pharmcogenomic

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; CHOLESTEROL; DRUG METABOLIZING ENZYME; EFAVIRENZ; HIGH DENSITY LIPOPROTEIN; HLA A ANTIGEN; HLA B ANTIGEN; LEUKOCYTE ANTIGEN; MULTIDRUG RESISTANCE PROTEIN 1; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

AFRICAN AMERICAN; ANAPHYLAXIS; ATHEROGENIC DYSLIPIDEMIA; CAUCASIAN; CENTRAL NERVOUS SYSTEM DISEASE; CHOLESTEROL BLOOD LEVEL; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG TOLERABILITY; DYSLIPIDEMIA; FEVER; FLU LIKE SYNDROME; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HYPOTENSION; INCIDENCE; LIPOPROTEIN BLOOD LEVEL; MAJOR HISTOCOMPATIBILITY COMPLEX; NAUSEA; PHARMACOGENOMICS; RASH; REVIEW; SERUM SICKNESS; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; VOMITING;

EID: 77953428321     PISSN: None     EISSN: 11787066     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. Pirmohamed M, Back DJ. The pharmacogenomics of HIV therapy. Pharmacogenomics J. 2001;1(4):243-253.
2. Kayser S. Pharmacogenomics and the potential for personalized therapeutics in cardiovascular disease. Prog Cardiovasc Nurs. 2007;22(2):104-107.
3. Haas DW, Ribaudo HJ, Kim RB, et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS. 2004;18(18):2391-2400.
4. Hammer SM, Eron JJ Jr, Reiss P, et al; International AIDS Society-USA. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA. 2008;300(5):555-570.
5. Palella FJ Jr. Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338(13):853-860.
6. Kilmarx PH. Global epidemiology of HIV. Curr Opin HIV AIDS. 2009;4(4):240-246.
7. Garber M. HIV-infected African Americans are willing to participate in HIV treatment trials. J Gen Intern Med. 2007;22(1):17-42.
8. Burroughs VJ, Maxey RW, Levy RA. Racial and ethnic differences in response to medicines: towards individualized pharmaceutical treatment. J Natl Med Assoc. 2002;94(10 Suppl):1-26.
9. Rodríguez-Nóvoa S, Barreiro P, Jiménez-Nacher I, Rendón A, Soriano V. Pharmacogenetics in HIV therapy. AIDS Rev. 2005;7(2):103-112.
10. Pourpak Z, Fazlollahi MR, Fattahi F. Understanding adverse drug reactions and drug allergies: principles, diagnosis and treatment aspects. Recent Pat Inflamm Allergy Drug Discov. 2008;2(1):24-46.
11. Trowsdale J, Campbell RD. Complexity in the major histocompatibility complex. Eur J Immunogenet. 1992;19(1-2):45-55.
12. Saag M, Balu R, Phillips E, et al; Study of Hypersensitivity to Abacavir and Pharmacogenetic Evaluation Study Team. High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. Clin Infect Dis. 2008;46:1111-1118.
13. Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med. 2008;358:568-579.
14. Hetherington S, Hughes AR, Mosteller M, et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet. 2002;359:1121-1122.
15. Hughes AR, Mosteller M, Bansal AT, et al; CNA30027 Study Team; CNA30032 Study Team. Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations. Pharmacogenomics. 2004;5(2):203-211.
16. Cressey TR, Lallemant M. Pharmacogenetics of antiretroviral drugs for the treatment of HIV-infected patients: an update. Infect Genet Evol. 2007;7(2):333-342.
17. Rauch A, Nolan D, Martin A, et al. Prospecitve genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study. Clin Infect Dis. 2006;43(1):99-102.
18. Mallal S, Nolan D, Witt C, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet. 2002;359(9308):727-732.
19. Lallemant MJ, Le Coeur G, Mary S, et al. Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. N Engl J Med. 2004;351(3):217-228.
20. Zhou SF. Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. Xenobiotica. 2008;38(7-8):802- 832.
21. Cupp MJ, Tracy TS. Cytochrome P450: new nomenclature and clinical implications. Am Fam Physician. 1998;57(1):107-116.
22. Ende M, Sahtoe C, Dieleman J, Burger D, Schaik R. Prevalence of single nucleotide polymorphisms in MDR-1 and CYP3 A genes within a heterogenous HIV-1-infected population and effect on nevirapine plasma levels. San Francisco, CA: Conference on Retroviruses and Opportunistic Infections; 2004.
23. Haas DW, Bartlett JA, Andersen JW, et al; Adult AIDS Clinical Trials Group. Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration. Clin Infect Dis. 2006;43(6):783-786.
24. Ritchie MD, Haas DW, Motsinger AA, et al. Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse transcriptase inhibitor hepatotoxicity. Clin Inf Dis. 2006;43:779-782.
25. Haas DW, Smeaton LM, Shafer RW, et al. Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study. J Infect Dis. 2005;192:1931-1942.
26. Saitoh A, Fletcher CV, Brundage R, et al. Efavirenz pharmacokinetics in HIV-1-infected children are associated with CYP2B6-G516T polymorphism. J Acquir Immune Defic Syndr. 2007;45(3):280-285.
27. Ribaudo HJ, Haas DW, Tierney C, et al; Adult AIDS Clinical Trials Group Study. Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study. Clin Infect Dis. 2006;42(3):401-407.
28. Friis-Møller N, Weber R, Reiss P, et al; DAD study group. Cardiovascular disease risk factors in HIV patients - association with antiretroviral therapy. Results from the DAD study. AIDS. 2003;17:1179-1193.
29. d'Arminio A, Sabin CA, Phillips AN, et al. Cardio- and cerebrovascular events in HIV-infected persons. AIDS. 2004;18:1811-1817.
30. Mary-Krause M, Cotte L, Simon A, Partisani M, Costagliola D. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS. 2003;17:2479-2486.
31. Fontas E, van Leth F, Sabin CA, et al. Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: Are different antiretroviral drugs associated with different lipid profiles? J Infect Dis. 2004;189:1056-1074.
32. Hui DY. Effects of HIV protease inhibitor therapy on lipid metabolism. Prog Lipid Res. 2003;42:81-92.
33. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med. 2005;352:48-62.
34. Bonnet E, Ruidavets JB, Tuech J, et al. Apoprotein c-III and E-containing lipoparticles are markedly increased in HIV-infected patients treated with protease inhibitors: Association with the development of lipodystrophy. J Clin Endocrinol Metab. 2001;86:296-302.
35. Cahn PE, Gatell JM, Squires K, et al. Atazanavir - a once-daily HIV protease inhibitor that does not cause dyslipidemia in newly treated patients: Results from two randomized clinical trials. J Int Assoc Physicians AIDS Care (Chic Ill). 2004;3:92-98.
36. Liang JS, Distler O, Cooper DA, et al. HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: A potential mechanism for protease inhibitor-induced hyperlipidemia. Nat Med. 2001;7:1327-1331.
37. Puro V. Effect of short-course of antiretroviral agents on serum triglycerides of healthy individuals. AIDS. 2000;14:2407-2408.
38. Olson RE. Discovery of the lipoproteins, their role in fat transport and their significance as risk factors. J Nutr. 1998;128(2 Suppl):439S-443S.
39. Segrest JP, Jones MK, De Loof H, Dashti N. Structure of Apolipoprotein B-100 in low denstiy lipoproteins. J Lipid Res. 2001;42(9):1346-1367.
40. Surguchov AP, Page GP, Smith L, Patsch W, Boerwinkle E. Polymorphic markers in apolipoprotein C-III gene flanking regions and hypertriglyceridemia. Arterioscler Thromb Vasc Biol. 1996;16:941-947.
41. Li WW, Dammerman MM, Smith JD, Metzger S, Breslow JL, Leff T. Common genetic variation in the promoter of the human apo CIII gene abolishes regulation by insulin and may contribute to hypertriglyceridemia. J Clin Invest. 1995;96:2601-2605.
42. Dammerman M, Sandkuijl LA, Halaas JL, Chung W, Breslow JL. An apolipoprotein CIII haplotype protective against hypertriglyceridemia is specified by promoter and 3′ untranslated region polymorphisms. Proc Natl Acad Sci U S A. 1993;90:4562-4566.
43. van Dijk KW, Rensen PC, Voshol PJ, Havekes LM. The role and mode of action of apolipoproteins CIII and AV: synergistic actors in triglyceride metabolism? Curr Opin Lipidol. 2004;15:239-246.
44. Dallinga-Thie GM, van Linde-Sibenius Trip M, Rotter JI, et al. Complex genetic contribution of the Apo AI-CIII-AIV gene cluster to familial combined hyperlipidemia. Identification of different susceptibility haplotypes. J Clin Invest. 1997;99:953-961.
45. Mahley RW, Rall SC Jr. Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet. 2000;1:507-537.
46. Tarr PE, Taffe P, Bleiber G, et al. Modeling the influence of APOC3, APOE, and TNF polymorphisms on the risk of antiretroviral therapy associated lipid disorders. J Infect Dis. 2005;191:1419-1426.
47. Fauvel JB, Ruidavets E, Ferrieres JB, et al. An interaction between apo C-III variants and protease inhibitors contributes to high triglyceride/low HDL levels in treated HIV patients. AIDS. 2001;15(18):2397-2406.
48. Gardner CD, Winkleby MA, Fortmann SP. Population frequency distribution of non-high-density lipoprotein cholesterol (Third National Health and Nutrition Examination Survey [NHANES III], 1988-1994). Am J Cardiol. 2000;86:299-304.
49. Foulkes AS, Wohl DA, Frank I, et al. Associations among race/ethnicity, ApoC-III genotypes, and lipids in HIV-1-infected individuals on antiretroviral therapy. PLoS Med. 2006;3(2):e52.